Sartorius Stedim Biotech SA (DIM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sartorius Stedim Biotech SA (DIM) has a cash flow conversion efficiency ratio of 0.030x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€129.50 Million ≈ $151.40 Million USD) by net assets (€4.25 Billion ≈ $4.97 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sartorius Stedim Biotech SA (DIM) market capitalisation for the company's overall valuation and market capitalisation.
Sartorius Stedim Biotech SA - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Sartorius Stedim Biotech SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sartorius Stedim Biotech SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sartorius Stedim Biotech SA ranked by their cash flow conversion efficiency. Explore DIM operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CNH Industrial N.V.
NYSE:CNH
|
0.018x |
|
KUBOTA CORP. ADR/20
F:KUOA
|
0.038x |
|
Alliant Energy Corp
NASDAQ:LNT
|
0.050x |
|
CELLN.TELEC.UNSP.ADR/1/2
F:4720
|
N/A |
|
IHH Healthcare Bhd
KLSE:5225
|
0.029x |
|
Banco Santander Chile
SN:BSANTANDER
|
-0.075x |
|
Lundin Gold Inc
TO:LUG
|
0.153x |
|
Toast Inc
NYSE:TOST
|
0.070x |
Annual Cash Flow Conversion Efficiency for Sartorius Stedim Biotech SA (2005–2025)
The table below shows the annual cash flow conversion efficiency of Sartorius Stedim Biotech SA from 2005 to 2025. View DIM stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.13 Billion ≈ $4.82 Billion |
€538.60 Million ≈ $629.68 Million |
0.131x | -35.56% |
| 2024-12-31 | €4.02 Billion ≈ $4.70 Billion |
€815.10 Million ≈ $952.94 Million |
0.203x | -27.45% |
| 2023-12-31 | €2.67 Billion ≈ $3.13 Billion |
€746.40 Million ≈ $872.62 Million |
0.279x | +14.65% |
| 2022-12-31 | €2.51 Billion ≈ $2.94 Billion |
€612.30 Million ≈ $715.84 Million |
0.244x | -39.35% |
| 2021-12-31 | €1.73 Billion ≈ $2.03 Billion |
€695.97 Million ≈ $813.66 Million |
0.402x | +42.84% |
| 2020-12-31 | €1.48 Billion ≈ $1.73 Billion |
€416.88 Million ≈ $487.38 Million |
0.281x | +6.75% |
| 2019-12-31 | €1.18 Billion ≈ $1.38 Billion |
€310.13 Million ≈ $362.57 Million |
0.263x | +21.07% |
| 2018-12-31 | €1.04 Billion ≈ $1.22 Billion |
€227.29 Million ≈ $265.72 Million |
0.218x | +9.51% |
| 2017-12-31 | €879.45 Million ≈ $1.03 Billion |
€174.69 Million ≈ $204.23 Million |
0.199x | -3.19% |
| 2016-12-31 | €763.56 Million ≈ $892.68 Million |
€156.66 Million ≈ $183.15 Million |
0.205x | -7.00% |
| 2015-12-31 | €647.22 Million ≈ $756.67 Million |
€142.79 Million ≈ $166.94 Million |
0.221x | +6.73% |
| 2014-12-31 | €538.51 Million ≈ $629.58 Million |
€111.31 Million ≈ $130.14 Million |
0.207x | +10.53% |
| 2013-12-31 | €481.84 Million ≈ $563.32 Million |
€90.11 Million ≈ $105.34 Million |
0.187x | +66.16% |
| 2012-12-31 | €434.72 Million ≈ $508.24 Million |
€48.93 Million ≈ $57.20 Million |
0.113x | -26.52% |
| 2011-12-31 | €395.63 Million ≈ $462.53 Million |
€60.59 Million ≈ $70.84 Million |
0.153x | -23.15% |
| 2010-12-31 | €365.07 Million ≈ $426.80 Million |
€72.76 Million ≈ $85.06 Million |
0.199x | -14.69% |
| 2009-12-31 | €393.20 Million ≈ $459.69 Million |
€91.86 Million ≈ $107.39 Million |
0.234x | +83.84% |
| 2008-12-31 | €371.65 Million ≈ $434.49 Million |
€47.23 Million ≈ $55.21 Million |
0.127x | +77.15% |
| 2007-12-31 | €362.76 Million ≈ $424.10 Million |
€26.02 Million ≈ $30.42 Million |
0.072x | -76.57% |
| 2006-12-31 | €168.93 Million ≈ $197.50 Million |
€51.72 Million ≈ $60.46 Million |
0.306x | +3.56% |
| 2005-12-31 | €148.35 Million ≈ $173.44 Million |
€43.85 Million ≈ $51.27 Million |
0.296x | -- |
About Sartorius Stedim Biotech SA
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more